I godt samarbeid med toneangivende oppdrettsaktører utvikler Calanus AS et beskyttelsesnett for oppdrettsnøter og oppdrettsfisk som over en forsøksperiode på 6 måneder gav hele 80% reduksjon i påslag av lakselus, samtidig som begroing på nøtene ble dramatisk redusert.

Beskyttelsesnettet – eller luseskjørtet – er basert på kunnskap og materialteknologi  utviklet for høsting av raudåte. Luseskjørtet testes nå videre hos 3 toneangivende oppdrettsaktører i Nordland, samtidig som at Calanus AS er i dialog med flere aktører om levering av luseskjørtet utprøving i andre oppdrettsregioner.

 Luseskjørtet er patentsøkt av Calanus AS med egne ansatte og ansatte i Nordlaks AS som oppfinnere. Målet er å gjøre produktet tilgjengelig for hele oppdrettsnæringen som et nytt miljøvennlig verktøy for å redusere påslag av lakselus.

For ytterligere informasjon om luseskjørtet, vennligst se (link >>)

• Salg av Calanus® Oil i Norge  – 20.08.12

• Calanus® Oil – Update – 20.08.12

• New publication on Calanus Oil - 02.03.2012

• New employees in Calanus AS – 21.10.2011

Alice Marie Pedersen (M. Sc.) has been employed as Researcher. She is currently conducting a 3-year Ph.D.-project regarding properties of Calanus Oil. Alice is a biochemist who has been working with stability of marine oils at the University of Tromsø.

Hogne Abrahamsen (M. Sc.) has been employed as Product Manager. Hogne has a key  role in Calanus’ business and market  development plans.  Hogne has previously held the position as Product Manager at Ayanda AS.

Åse Kristine Rognmo Mikalsen (M. Sc.) has been employed as Quality Assurance Manager (from January 1, 2012). Åse has broad QC/QA-experience from Ayanda AS and will be responsible for further development of the quality assurance program of Calanus.

• Update on human clinical study with Calanus® Oil – 20.08.2011

The University Hospital North-Norway HF (UNN) has included 117 participants in the double-blinded, placebo-controlled  clinical study titled “Effect of Calanus Oil on Intra-Abdominal Fat, Glucose Tolerance and Lipids in Man”. 

• Started inclusion in human clinical study with Calanus® Oil - 24.03.2011

The University Hospital North-Norway HF (UNN) has now started to include participants in the clinical study titled “Effect of Calanus Oil on Intra-Abdominal Fat, Glucose Tolerance and Lipids in Man”. The study is double-blinded, randomized and placebo-controlled, and it is the plan to recruit 120 healthy, moderately obese volunteers.

• Presentation at BIOPROSP 2011 – 24.02.2011

A presentation regarding biomedical research results with Calanus Oil was given by  Professor Terje Larsen at BIOPROSP 2011. The presentation concludes that Calanus Oil is able to counteract obesity-related alterations in metabolism, and potentially could reduce effects on organ function associated with obesity and type 2 diabetes.

2010

• Signed agreement to conduct human clinical study with Calanus® Oil – 25.10.2010 

Calanus AS has today signed a Clinical Study Agreement with The University Hospital North-Norway HF (UNN), represented by TTO Nord AS (Research Foundation), to conduct a clinical study titled “Effect of Calanus Oil on Intra-Abdominal Fat, Glucose Tolerance and Lipids in Man”. The study is double-blinded, randomized and placebo-controlled, and it is the plan to recruit 120 healthy, moderately obese volunteers.  Subject to final Independent Ethics Committee approval, the study is due to begin in January 2011.

• Presentation at MIC-2010 – 21.09.2010

Calanus AS, represented by Professor emeritus Jan Raa, gave a presentation at The First International Marine Ingredients Conference Norway held in Oslo on September 20-21, 2010. Please follow this link to a PDF-copy of the presentation (link >>)

• Positive outcome of human pilot study with Calanus® Oil – 25.07.2010

Calanus AS has completed a first human clinical study with its dietary supplement Calanus® Oil, to confirm its safety and tolerability (“Effects of oil from Calanus finmarchicus in human subjects. A pilot study”). The study concluded that Calanus® Oil in the doses given (up to 4 grams per day) appeared to be safe and well tolerated. The study was conducted at the University Hospital North-Norway HF (UNN) under the supervision of Professor Rolf Jorde.

• Issued patent for technology for harvesting of Calanus finmarchicus– 19.07.2010

A patent covering a towing system for scouping and harvesting of small crustaceans such as Calanus finmarchicus copepods has been issued to Calanus AS in Norway. The system has several unique features, including a sectioned inner net, designed to reduce towing resistance and improve selectivity. The system has been successfully tested under practical conditions, and shown to significantly reduce fuel consumption and improve harvesting efficiency.

2009

• Filed patent application – 12.06.2009

Calanus AS has filed a patent application covering preparation, formulation and use of an oil composition derived from copepods (Calanus finmarchicus) to reduce accumulation of visceral fat and the risk of obesity related disorders.

• Presentation at BIOPROSP 2009 – 22.02.2009

Calanus AS gave a presentation at the Bioprop-2009 meeting held in Tromsø, Norway on February 22, 2009. Please follow this link to a PDF-copy of the presentation (link >>)

• Filed patent application – 05.01.2009

Calanus AS has filed a patent application covering preparation and formulation of an oil composition derived from copepods (Calanus finmarchicus), and the use thereof to prevent or treat cardiovascular disease.